ArticleLupus science & medicine2026
Circulating kidney injury molecule-1 as a prognostic biomarker for long-term renal outcomes in lupus nephritis: a retrospective cohort study.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether circulating kidney injury molecule-1 (KIM-1) predicts long-term renal outcomes in lupus nephritis (LN), including relapse, progression to end-stage kidney disease (ESKD) and mortality.
methodsThis retrospective cohort study included 63 Japanese patients with biopsy-confirmed LN who were treated at Kanazawa University Hospital between 1990 and 2022. After excluding 17 patients who did not meet the eligibility criteria, 46 patients were included in the final analysis. Circulating KIM-1 levels were measured in serum samples collected at the time of renal biopsy prior to treatment or additional treatment. Patients were stratified into low-KIM-1 and high-KIM-1 groups using the median value (153 pg/mL) as the cut-off. The primary endpoints were LN relapse, ESKD and all-cause mortality. Survival was analysed using Kaplan-Meier curves and Cox proportional hazards models.
resultsDuring a median follow-up of 127 months, nine patients (20%) experienced relapse, four (9%) developed ESKD and six (13%) died. The high-KIM-1 group had lower baseline renal function, greater proteinuria, a higher frequency of Class IV histology and higher activity index scores. Kaplan-Meier analysis demonstrated significantly lower LN relapse-free (p=0.027; log-rank) and ESKD-free survival (p=0.049) in the high-KIM-1 group. In the multivariable Cox regression analysis, circulating KIM-1 was independently associated with LN relapse (per-IQR HR: 1.92, 95% CI 1.07 to 3.45; p=0.029).
conclusionElevated circulating KIM-1 at the time of renal biopsy was associated with adverse long-term renal outcomes in LN and independently associated with relapse, although its incremental predictive value beyond conventional clinical markers was modest. KIM-1 may support early risk stratification and individualised treatment; however, prospective validation in larger cohorts is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.